We are testing the drug Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma. This study aims to explore its potential effectiveness in treating this challenging condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a type of aggressive cancer that affects the lymphatic system, where the disease returns after treatment or does not respond to initial therapy. Patients may experience symptoms such as swollen lymph nodes, fever, night sweats, and unexplained weight loss.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
